Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis
Objective The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods This study included 341 participants of the Nordic Rheumatic Diseases Strategy Trials and Re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11756 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542399241388032 |
|---|---|
| author | Georgios K. Vasileiadis Yuan Zhang Tahzeeb Fatima Ronald van Vollenhoven Jon Lampa Bjorn Gudbjornsson Espen A. Haavardsholm Dan Nordström Gerdur Grondal Kim Hørslev‐Petersen Kristina Lend Marte S. Heiberg Merete Lund Hetland Michael Nurmohamed Till Uhlig Tuulikki Sokka‐Isler Anna Rudin Cristina Maglio |
| author_facet | Georgios K. Vasileiadis Yuan Zhang Tahzeeb Fatima Ronald van Vollenhoven Jon Lampa Bjorn Gudbjornsson Espen A. Haavardsholm Dan Nordström Gerdur Grondal Kim Hørslev‐Petersen Kristina Lend Marte S. Heiberg Merete Lund Hetland Michael Nurmohamed Till Uhlig Tuulikki Sokka‐Isler Anna Rudin Cristina Maglio |
| author_sort | Georgios K. Vasileiadis |
| collection | DOAJ |
| description | Objective The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods This study included 341 participants of the Nordic Rheumatic Diseases Strategy Trials and Registries trial with untreated early RA, randomized at baseline into four treatment arms: methotrexate combined with (1) prednisolone, (2) certolizumab, (3) abatacept, or (4) tocilizumab. Follow‐up was up to 48 weeks. Adipokines were measured in plasma at baseline with enzyme‐linked immunosorbent assay. The primary outcome for this report was the difference in remission (Clinical Disease Activity Index [CDAI] ≤2.8) over 48 weeks stratified by median adipokine levels. Results At baseline, levels of adiponectin and leptin were not associated with markers of RA activity, whereas participants with higher resistin levels had higher C‐reactive protein (CRP) levels, swollen joint count, and Disease Activity Score in 28 joints based on CRP compared to participants with lower resistin. Overall, participants with baseline adipokine levels above the median and those with adipokine levels below the median had similar mean CDAI and changes in CDAI throughout follow‐up for up to 48 weeks. Adjusted Cox proportional hazards models did not show any effect of baseline adiponectin, leptin, and resistin levels on the likelihood of achieving CDAI remission (adiponectin: hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.80–1.45, P = 0.62; leptin: HR 0.89, 95% CI 0.64–1.26, P = 0.52; resistin: HR 0.86, 95% CI 0.65–1.13, P = 0.26). Conclusion Baseline adiponectin, leptin, and resistin levels are not associated with the likelihood of achieving CDAI remission over 48 weeks of treatment in a large cohort of people with untreated early RA. |
| format | Article |
| id | doaj-art-babbd4d1dafb4da7a8b3f3774a82f5fc |
| institution | Kabale University |
| issn | 2578-5745 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj-art-babbd4d1dafb4da7a8b3f3774a82f5fc2025-02-04T06:21:23ZengWileyACR Open Rheumatology2578-57452025-01-0171n/an/a10.1002/acr2.11756Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid ArthritisGeorgios K. Vasileiadis0Yuan Zhang1Tahzeeb Fatima2Ronald van Vollenhoven3Jon Lampa4Bjorn Gudbjornsson5Espen A. Haavardsholm6Dan Nordström7Gerdur Grondal8Kim Hørslev‐Petersen9Kristina Lend10Marte S. Heiberg11Merete Lund Hetland12Michael Nurmohamed13Till Uhlig14Tuulikki Sokka‐Isler15Anna Rudin16Cristina Maglio17University of Gothenburg Gothenburg SwedenUniversity of Gothenburg Gothenburg SwedenUniversity of Gothenburg Gothenburg SwedenKarolinska University Hospital, Stockholm, Sweden, and Amsterdam University Medical Centers Amsterdam The NetherlandsKarolinska University Hospital Stockholm SwedenLandspitali University Hospital and University of Iceland Reykjavik IcelandDiakonhjemmet Hospital Oslo NorwayHelsinki University Hospital and University of Helsinki Helsinki FinlandLandspitali University Hospital and University of Iceland Reykjavik IcelandUniversity Hospital of Southern Denmark, Sønderborg, Denmark, and University of Southern Denmark Odense DenmarkKarolinska University Hospital, Stockholm, Sweden, and Amsterdam University Medical Centers Amsterdam The NetherlandsUniversity of Helsinki Helsinki FinlandRigshospitalet, Glostrup, Denmark, and University of Copenhagen Copenhagen DenmarkAmsterdam University Medical Centers and Amsterdam Rheumatology and Immunology Center Amsterdam The NetherlandsDiakonhjemmet Hospital and University of Oslo Oslo NorwayUniversity of Eastern Finland Joensuu, Finland, and Jyväskylä Central Hospital Jyväskylä FinlandUniversity of Gothenburg and Sahlgrenska University Hospital Gothenburg SwedenUniversity of Gothenburg and Sahlgrenska University Hospital Gothenburg SwedenObjective The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods This study included 341 participants of the Nordic Rheumatic Diseases Strategy Trials and Registries trial with untreated early RA, randomized at baseline into four treatment arms: methotrexate combined with (1) prednisolone, (2) certolizumab, (3) abatacept, or (4) tocilizumab. Follow‐up was up to 48 weeks. Adipokines were measured in plasma at baseline with enzyme‐linked immunosorbent assay. The primary outcome for this report was the difference in remission (Clinical Disease Activity Index [CDAI] ≤2.8) over 48 weeks stratified by median adipokine levels. Results At baseline, levels of adiponectin and leptin were not associated with markers of RA activity, whereas participants with higher resistin levels had higher C‐reactive protein (CRP) levels, swollen joint count, and Disease Activity Score in 28 joints based on CRP compared to participants with lower resistin. Overall, participants with baseline adipokine levels above the median and those with adipokine levels below the median had similar mean CDAI and changes in CDAI throughout follow‐up for up to 48 weeks. Adjusted Cox proportional hazards models did not show any effect of baseline adiponectin, leptin, and resistin levels on the likelihood of achieving CDAI remission (adiponectin: hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.80–1.45, P = 0.62; leptin: HR 0.89, 95% CI 0.64–1.26, P = 0.52; resistin: HR 0.86, 95% CI 0.65–1.13, P = 0.26). Conclusion Baseline adiponectin, leptin, and resistin levels are not associated with the likelihood of achieving CDAI remission over 48 weeks of treatment in a large cohort of people with untreated early RA.https://doi.org/10.1002/acr2.11756 |
| spellingShingle | Georgios K. Vasileiadis Yuan Zhang Tahzeeb Fatima Ronald van Vollenhoven Jon Lampa Bjorn Gudbjornsson Espen A. Haavardsholm Dan Nordström Gerdur Grondal Kim Hørslev‐Petersen Kristina Lend Marte S. Heiberg Merete Lund Hetland Michael Nurmohamed Till Uhlig Tuulikki Sokka‐Isler Anna Rudin Cristina Maglio Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis ACR Open Rheumatology |
| title | Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis |
| title_full | Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis |
| title_fullStr | Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis |
| title_full_unstemmed | Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis |
| title_short | Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis |
| title_sort | circulating adipokines and response to treatment in patients with early rheumatoid arthritis |
| url | https://doi.org/10.1002/acr2.11756 |
| work_keys_str_mv | AT georgioskvasileiadis circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT yuanzhang circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT tahzeebfatima circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT ronaldvanvollenhoven circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT jonlampa circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT bjorngudbjornsson circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT espenahaavardsholm circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT dannordstrom circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT gerdurgrondal circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT kimhørslevpetersen circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT kristinalend circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT martesheiberg circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT meretelundhetland circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT michaelnurmohamed circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT tilluhlig circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT tuulikkisokkaisler circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT annarudin circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis AT cristinamaglio circulatingadipokinesandresponsetotreatmentinpatientswithearlyrheumatoidarthritis |